AMLX

Amylyx Pharmaceuticals, Inc. (AMLX) | Rumor.io

Amylyx Pharmaceuticals

AMLX

Attention (50-day avg)0%

Attention rank (50-day avg)#716

Bullish sentiment (50-day avg)56%

Price to earnings ratio2.54

Market capitalization3.8B

Earnings per share-1.43

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-144.7M

Social

What share of all stock conversation is about AMLX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% -0.01	0% 0

Aug 21

Amylyx Pharmaceuticals, Inc. (AMLX) is being shorted at $41.25+ with a stop-loss at $42.55, with the stock deemed worth no more than $28 due to its 2-year development timeline.
AMLX has been classified as a long-term catalyst play, with a deep clinical pipeline of 10 active trials and a 79% conviction level for a potential price increase.
AMLX has been involved in a $500M upsized offering, with $471.7M in net proceeds, and is expected to close on August 21.

Generated by AI

Sentiment

Of the messages about AMLX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	23.08%	12% -48.71	71.88% -16.82
Bearish	—	76.92%	88% +48.71	28.12% +16.82

Bullish· Aug 19

Amylyx Pharmaceuticals has a promising pipeline with 10 active trials, which could lead to a significant increase in its stock price.
The company is on track to achieve Phase 3 wins, which could result in a 64% spike in its stock price, making it a strong buy and hold opportunity.
The stock's technical analysis is favorable, with an RSI of 85.4, MACD rising, and a low down-day volume, indicating accumulation and a potential breakout above $39.

Bearish· Aug 19

The offering price for $AMLX is expected to be disclosed soon, which could lead to a temporary drop in the stock price.
The company's drug is years away from generating significant revenue, and the recent capital raise could lead to heavy dilution for existing shareholders.
The stock's momentum has been lost due to the offering, and it will likely take a significant catalyst to recover the lost momentum and volume.

Generated by AI

Topics

Of the messages about AMLX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	88.57%	36.74%
Technical Analysis	0%	0%	11.43%	5.9%
Analysts	0%	0%	0%	50.76%
Macro	0%	0%	0%	3.64%
Earnings	0%	0%	0%	2.46%
Controversies	0%	0%	0%	0.49%

Analysts· Feb 1

SVB Leerink initiates coverage on Amylyx Pharmaceuticals with an "outperform" rating and a price target of $50.
HC Wainwright initiates coverage on Amylyx Pharmaceuticals with a "buy" rating and a price target of $35.
Goldman Sachs initiates coverage on Amylyx Pharmaceuticals with a "buy" rating and a price target of $36.

Announcements· Aug 18

Amylyx Pharmaceuticals' ($AMLX) avexitide met the primary endpoint in the Phase 3 LUCIDITY trial, demonstrating a 55% reduction in severe hypoglycemic events compared to placebo.
The trial's positive results led to a significant increase in the company's stock price, with shares surging by 45-50% and the market cap reaching $3.6B.
Amylyx' avexitide has already received Breakthrough Therapy and Orphan Drug designations, and the company plans to submit a New Drug Application (NDA) for approval.

Technical Analysis· Mar 8

$AMLX has a potential buy opportunity at $2.84 and $2.85, where stop losses may be busted.
The stock's daily chart shows it is back at the 50-day SMA, with a price of $16.
$AMLX has a volume-weighted average price (VWAP) of $3.28, which may be a key level of support or resistance.

Generated by AI

Community

Of the messages about AMLX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	50%	53.33%	45.88%	46.95%
Newcomers	50%	46.67%	54.12%	53.05%

Regulars· Aug 20

The recent $500 million public offering of Amylyx Pharmaceuticals, Inc. (AMLX) was priced at $35.50 per share, and the company has a total of $750 million in cash reserves.
The company's valuation and market potential are being discussed, with one participant noting that the company's Total Addressable Market (TAM) is $17 billion, and a 30% capture rate would be $5 billion.
Amylyx Pharmaceuticals, Inc. is considered a potential acquisition target, with one participant noting that the company's pristine clean balance sheet and de-risked position make it an attractive candidate for a buyout.

Newcomers· Aug 21

The stock's price is considered overvalued by some, with a target price of $28 despite recent positive phase 3 data.
There is a significant short position in the stock, with 14% of shares available to trade being sold short.
The company has a deep clinical pipeline with 10 active trials, and is classified as a LONG-term catalyst play with a high conviction rating of 79/100.

Generated by AI

News

Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum

CAMBRIDGE, Mass., September 23, 2026--Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum

6d agoYahoo Finance

Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference

CAMBRIDGE, Mass., September 08, 2026--Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference

21d agofinance.yahoo.com

Should Eli Lilly Investors Be Worried About a Threat From Amylyx?

Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate.

1mo agoYahoo Finance

Guggenheim raises Amylyx stock price target on financing, trial data

1mo agoInvesting.com

Amylyx Pharmaceuticals Inc (AMLX) Gets a Buy from LifeSci Capital

Detailed price information for Amylyx Pharmaceuticals Inc (AMLX-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week

The biotech delivered excellent news from the laboratory.

1mo agoYahoo Finance

Also Discussed

Investors talking about AMLX also mention

#	Name	Attention
1	Nanobiotix S.A. ADRNBTX	0%0
2	TERN - Terns Pharmaceuticals, Inc.	——
3	Biohaven Ltd.BHVN	0%-0.01
4	MDxHealth SAMDXH	0%0
5	Acumen Pharmaceuticals, Inc.ABOS	0%new
6	SWTX - SpringWorks Therapeutics, Inc.	——
7	SLRN - Acelyrin, Inc.	——
8	DAWN - Day One Biopharmaceuticals, Inc.	——
9	Bicycle Therapeutics plc - ADRBCYC	0%0
10	Alector Inc.ALEC	0%new

Amylyx Pharmaceuticals, Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for diseases with significant unmet medical needs. The company’s current pipeline centers on endocrine and neurodegenerative disorders, with avexitide as its lead investigational program. Avexitide is being studied as a first-in-class GLP-1 receptor antagonist for conditions linked to excessive insulin activity, including post-bariatric hypoglycemia and congenital hyperinsulinism. Amylyx also advances additional investigational therapies across other rare and serious diseases, reflecting a research portfolio built around well-defined biological targets and measurable clinical outcomes. Headquartered in Cambridge, Massachusetts, Amylyx Pharmaceuticals plays a role in the biotechnology market as a developer of targeted treatments for patients facing limited therapeutic options.

Website

Location

55 Cambridge Parkway

Cambridge, MA, 02142

United States

Social

What share of all stock conversation is about AMLX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% -0.01	0% 0

Aug 21

Amylyx Pharmaceuticals, Inc. (AMLX) is being shorted at $41.25+ with a stop-loss at $42.55, with the stock deemed worth no more than $28 due to its 2-year development timeline.
AMLX has been classified as a long-term catalyst play, with a deep clinical pipeline of 10 active trials and a 79% conviction level for a potential price increase.
AMLX has been involved in a $500M upsized offering, with $471.7M in net proceeds, and is expected to close on August 21.

Generated by AI

Sentiment

Of the messages about AMLX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	23.08%	12% -48.71	71.88% -16.82
Bearish	—	76.92%	88% +48.71	28.12% +16.82

Bullish· Aug 19

Amylyx Pharmaceuticals has a promising pipeline with 10 active trials, which could lead to a significant increase in its stock price.
The company is on track to achieve Phase 3 wins, which could result in a 64% spike in its stock price, making it a strong buy and hold opportunity.
The stock's technical analysis is favorable, with an RSI of 85.4, MACD rising, and a low down-day volume, indicating accumulation and a potential breakout above $39.

Bearish· Aug 19

The offering price for $AMLX is expected to be disclosed soon, which could lead to a temporary drop in the stock price.
The company's drug is years away from generating significant revenue, and the recent capital raise could lead to heavy dilution for existing shareholders.
The stock's momentum has been lost due to the offering, and it will likely take a significant catalyst to recover the lost momentum and volume.

Generated by AI

Topics

Of the messages about AMLX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	88.57%	36.74%
Technical Analysis	0%	0%	11.43%	5.9%
Analysts	0%	0%	0%	50.76%
Macro	0%	0%	0%	3.64%
Earnings	0%	0%	0%	2.46%
Controversies	0%	0%	0%	0.49%

Analysts· Feb 1

SVB Leerink initiates coverage on Amylyx Pharmaceuticals with an "outperform" rating and a price target of $50.
HC Wainwright initiates coverage on Amylyx Pharmaceuticals with a "buy" rating and a price target of $35.
Goldman Sachs initiates coverage on Amylyx Pharmaceuticals with a "buy" rating and a price target of $36.

Announcements· Aug 18

Amylyx Pharmaceuticals' ($AMLX) avexitide met the primary endpoint in the Phase 3 LUCIDITY trial, demonstrating a 55% reduction in severe hypoglycemic events compared to placebo.
The trial's positive results led to a significant increase in the company's stock price, with shares surging by 45-50% and the market cap reaching $3.6B.
Amylyx' avexitide has already received Breakthrough Therapy and Orphan Drug designations, and the company plans to submit a New Drug Application (NDA) for approval.

Technical Analysis· Mar 8

$AMLX has a potential buy opportunity at $2.84 and $2.85, where stop losses may be busted.
The stock's daily chart shows it is back at the 50-day SMA, with a price of $16.
$AMLX has a volume-weighted average price (VWAP) of $3.28, which may be a key level of support or resistance.

Generated by AI

Community

Of the messages about AMLX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	50%	53.33%	45.88%	46.95%
Newcomers	50%	46.67%	54.12%	53.05%

Regulars· Aug 20

The recent $500 million public offering of Amylyx Pharmaceuticals, Inc. (AMLX) was priced at $35.50 per share, and the company has a total of $750 million in cash reserves.
The company's valuation and market potential are being discussed, with one participant noting that the company's Total Addressable Market (TAM) is $17 billion, and a 30% capture rate would be $5 billion.
Amylyx Pharmaceuticals, Inc. is considered a potential acquisition target, with one participant noting that the company's pristine clean balance sheet and de-risked position make it an attractive candidate for a buyout.

Newcomers· Aug 21

The stock's price is considered overvalued by some, with a target price of $28 despite recent positive phase 3 data.
There is a significant short position in the stock, with 14% of shares available to trade being sold short.
The company has a deep clinical pipeline with 10 active trials, and is classified as a LONG-term catalyst play with a high conviction rating of 79/100.

Generated by AI

Amylyx Pharmaceuticals

Social

Aug 21

Bullish· Aug 19

Bearish· Aug 19

Analysts· Feb 1

Announcements· Aug 18

Technical Analysis· Mar 8

Regulars· Aug 20

Newcomers· Aug 21

Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum

Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference

Should Eli Lilly Investors Be Worried About a Threat From Amylyx?

Guggenheim raises Amylyx stock price target on financing, trial data

Amylyx Pharmaceuticals Inc (AMLX) Gets a Buy from LifeSci Capital

Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week

Also Discussed

Amylyx Pharmaceuticals, Inc.

Company Information

Location

Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum

Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference

Should Eli Lilly Investors Be Worried About a Threat From Amylyx?

Guggenheim raises Amylyx stock price target on financing, trial data

Amylyx Pharmaceuticals Inc (AMLX) Gets a Buy from LifeSci Capital

Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week

Also Discussed

Social

Aug 21

Bullish· Aug 19

Bearish· Aug 19

Analysts· Feb 1

Announcements· Aug 18

Technical Analysis· Mar 8

Regulars· Aug 20

Newcomers· Aug 21